Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Adults of either sex 18 to 75 years of age, inclusive, with a diagnosis of primary hypercholesterolemia (familial and nonfamilial) or mixed hyperlipidemia (increased LDL-C and triglycerides \[TG\])~* must be free of any clinically significant disease, other than primary hypercholesterolemia or mixed hyperlipidemia that would knowingly interfere with study evaluations~* must be willing to adhere to dietary recommendations, protocol requirements, and provide written informed consent~Exclusion Criteria:~The participant will be excluded from entry if ANY of the criteria listed below are met:~* use of any investigational drug within 30 days of study entry~* female of childbearing potential or lactating~* postmenopausal (or perimenopausal) woman who is currently experiencing hot flashes (e.g. within 30 days of study entry~* homozygous familial hypercholesterolemia~* congestive heart failure New York Heart Association (NYHA) Class III or IV~* uncontrolled hypertension on or off therapy~* cardiac arrhythmia requiring medication~* clinical atherosclerotic disease that confers high risk for coronary heart disease (CHD) events (e.g. clinical CHD, symptomatic carotid artery disease, peripheral arterial disease, abdominal aortic aneurysm)~* Type 1 Diabetes Mellitus~* Type 2 Diabetes Mellitus~* history of mental instability, drug/alcohol abuse or who has been treated or is being treated for severe psychiatric illness, which in the opinion of the investigator, may interfere with optimal participation in the study~* gastrointestinal ulcer within 3 months of study entry~* history of coagulopathy~* history of gout~* known active or chronic hepatic or biliary disease.~* known significant impairment of renal function, dysproteinemia, nephrotic syndrome, or other renal disease~* body mass index \>40 kg/m\^2~* taking non-steroidal anti-inflammatory drugs (NSAIDS) (acetaminophen and cyclooxygenase-2 \[COX-2\] inhibitors are allowed)~* taking more than 100 mg aspirin per day~* being treated with corticosteroids (oral, intramuscular, or intravascular)~* more than 3 alcoholic beverages per day or its equivalent (one drink equals 1.5 ounces of 80 proof liquor or equivalent) during study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SCH 900271 15 mg (Type: EXPERIMENTAL): Participants receive SCH 900271 15 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
- SCH 900271 10 mg (Type: EXPERIMENTAL): Participants receive SCH 900271 10 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
- SCH 900271 5 mg (Type: EXPERIMENTAL): Participants receive SCH 900271 5 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
- SCH 900271 2.5 mg (Type: EXPERIMENTAL): Participants receive SCH 900271 2.5 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
- SCH 900271 1 mg (Type: EXPERIMENTAL): Participants receive SCH 900271 1 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Participants receive two placebo tablets once daily in the morning with water in a fasted state for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).